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Abstract
Vascular malformations are developmental congenital abnormalities of the vascular system which may involve any
segment of the vascular tree such as capillaries, veins, arteries, or lymphatics. Arteriovenous malformations (AVMs)
are congenital vascular lesions, initially described as “erectile tumors,” characterized by atypical aggregation of
dilated arteries and veins. They may occur in any part of the body, including the brain, heart, liver, and skin. Severe
clinical manifestations occur only in the brain. There is absence of normal vascular structure at the subarteriolar
level and dearth of capillary bed resulting in aberrant arteriovenous shunting. The causative factor and pathogenic
mechanisms of AVMs are unknown. Importantly, no marker proteins have been identified for AVM. AVM is a high
flow vascular malformation and is considered to develop because of variability in the hemodynamic forces of
blood flow. Altered local hemodynamics in the blood vessels can affect cellular metabolism and may trigger
epigenetic factors of the endothelial cell. The genes that are recognized to be associated with AVM might be
modulated by various epigenetic factors. We propose that AVMs result from a series of changes in the DNA
methylation and histone modifications in the genes connected to vascular development. Aberrant epigenetic
modifications in the genome of endothelial cells may drive the artery or vein to an aberrant phenotype. This
review focuses on the molecular pathways of arterial and venous development and discusses the role of hemodynamic
forces in the development of AVM and possible link between hemodynamic forces and epigenetic mechanisms in the
pathogenesis of AVM.
Background
International Society for the Study of Vascular Anomal-
ies (ISSVA) has categorized vascular anomalies into two
primary biological categories: (1) vascular neoplasms
and (2) vascular malformations [1]. Vascular neoplasms
are characterized by increased endothelial cell turn over
whereas vascular malformations are not [2]. Vascular
malformations are structural abnormalities which affect
any part of the vascular system such as artery, vein,
capillary or lymphatics. They can occur in any part of
the human body and can be present at any age [3].
Arteriovenous malformation (AVM) was initially de-
scribed and classified as a separate pathological entity in
mid-1800s by Luschka (1854) and Virchow (1863) [4, 5].
Surgical exposure of AVM was first performed by
Giordano in the year 1889; later, Green and Vaugham
in the year 1972 initiated the era of microsurgery treat-
ment for AVM [6, 7]. There have been several attempts to
classify vascular malformation based on the anatomic ap-
pearance, arteriovenous shunting, hemodynamics, and
contrast angiographic appearance, but the complexity in
disease status had made classification of vascular malfor-
mations very difficult [8–11]. Hamburg classification sys-
tem categorized vascular malformations based on the
predominant vascular defect whether it is arterial,
venous, arteriovenous, lymphatic, or combined. This
classification system is currently widely accepted by
pathologists [12]. Although vascular malformations
may develop in any part of the body, the cerebral
vascular malformations are the most severe. They are
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divided into four types: arteriovenous malformations,
developmental venous anomalies, cavernous malfor-
mations, and capillary telangiectasias [13]. This review
focuses on the molecular mechanisms in the develop-
ment of cerebral arteriovenous malformations.
Structural anomalies in arteriovenous
malformations
Arteriovenous malformations are high-flow vascular
malformations characterized by direct contact of arteries
to veins without an intervening capillary bed. AVM con-
sists of three components: a group of anomalous blood
vessels (nidus), a feeding artery, and a draining vein.
Feeding artery could be from anterior (internal carotid,
anterior cerebral, middle cerebral), posterior (posterior
cerebral, vertebra basilar system), or extra cranial vessels,
and there can be single or multiple feeding arteries.
Based on the hemodynamic contribution to AVM, it can
be a dominant feeder or a supplementary feeder. AVM is
often characterized by a single large draining vein,
though multiple draining veins can also be present.
Draining vein can be either superficial or deep centered
[12–14]. Anomalous blood vessels are grossly divided
into three groups: type A, resembles an arterial structure
with duplication of elastic lamina and reduced or scanty
medial muscular layer; type B, similar to hypertrophic or
degenerative veins with scarcity of internal elastic lamina
or elastic fibers; and type C, consists of vessels less than
150 μm in diameter intervened between type A and type
B vessels with a prominent increase in elastic fibers [15]
(Fig. 1b). Lesions of AVM can be either focal or diffused.
Focal lesions are highly compact with no intervening
cerebral parenchyma, whereas diffused lesions have nor-
mal cerebral tissue entrapped between blood vessels
[14]. Historical concept on the congenital nature of
AVM is challenged by the recurrence of AVM, even after
complete surgical removal [16–22].
There is no sex difference prediction for AVM inci-
dence, and the clinical course of the disease is similar in
both males and females [23]. Cerebral hemorrhage is the
common presenting symptom which leads to diagnosis
of AVM. Epileptic fits could also be a presenting symp-
tom. Epileptic fits could be seen even 9 years before
AVM is diagnosed [16–24]. Other presenting signs of
AVM include headaches, asymptomatic bruits, migraine,
psychiatric disorders, visual field defects, dizziness, bal-
ance disturbances, and migraine [25, 26]. AVMs can
occur in any lobe of the brain; the majority of AVMs are
supratentorial with the parietal lobe being frequently af-
fected. The size of the AVM can vary from 2 to 6 cm.
The small and deep-centered AVMs are more prone to
rupture than large AVMs [24, 25]. Computed tomo-
graphic angiography, magnetic resonance angiography,
and cerebral angiography are used to visualize AVM
(Fig. 1a). There are several modalities available for the
management of AVM. They include stereotactic radio-
therapy, microsurgical resection, and endovascular
embolization; operative treatment is most preferred to
prevent the intermittent risk of intracranial hemorrhage
and for complete eradication of the disease [27].
Molecular basis of AVM pathogenesis
Our understanding about AVM and its nature of devel-
opment in the brain are evolving rapidly. The lesions are
no longer considered as static lesions. They are highly
dynamic with features of rapid growth, remodeling, re-
gression, and de novo formation even after complete
surgical removal [16–22, 28]. Two basic approaches have
been followed to identify the genetic basis of AVMs in
humans: (i) the family linkage analysis in patients with
AVM and (ii) analysis of the defective genes using post-
operative specimens [14]. In most cases, it has been ob-
served that aberrant molecular signaling in the normal
vasculogenesis process leads to vascular malformations.
AVM as congenital lesions is associated with hereditary
hemorrhagic telangiectasia (HHT), Wyburn-Mason syn-
drome, Osler-Weber-Rendu disease, and Sturge-Weber
syndrome [29–33]. The importance of single nucleotide
A B
Fig. 1 a Cerebral angiogram of an AVM in frontal lobe of the brain. Nidus (thick arrow) and feeding artery (thin arrow). b Photomicrograph of an
AVM in the temporal lobe of the brain (hematoxylin-eosin ×4)
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polymorphisms in several genes linked to angiogenesis
and inflammation and their association for AVM devel-
opment have been reviewed [34]. The presence of muta-
tions in the genes of endoglin and activin receptor-like
kinase 1 predisposes to aberrant TGF-beta signaling and
is associated with HHT. These mutations commonly
lead to loss of function in the genes associated with
TGF-beta signaling [35]. It has also been shown that
genes that code for angiopoietins (ANGPT1 and
ANGPT2) and their receptor TIE-2 have a crucial role
in angiogenesis and vascular stability and there are re-
ports available that in AVM, there is an imbalance of
TIE-2-angiopoietin system [36].
Development of blood vessels
Anatomists long ago have demonstrated morphological
differences between arteries and veins. The primary ana-
tomical difference is that veins have thin walls with
valves whereas arteries have thick muscular walls and do
not have any valves. Functionally, they differ as arteries
carry oxygenated blood whereas veins carry deoxygen-
ated blood except in pulmonary circulation where it is
reversed [37]. During development, how the endothelial
cells are committed to be an artery or a vein or a capil-
lary is a subject of much debate. The morphological fea-
tures of artery and vein are thought to be acquired
during developmental stages on exposure to various
hemodynamic forces. Recent advances in vascular and
molecular biology have identified that hemodynamic
forces as well as genetic factors have significant roles in
determining the fate of an endothelial cell, either of an
artery or a vein. Studies on vascular development using
various experimental models have identified unique mo-
lecular markers expressed by arteries and veins and
those that are vital to maintain their identity [38–48]
(Table 1). Some studies have also focussed on micro-
environment that is important in governing venous/ar-
terial identity [49, 50]. The genetic factors which
determine the arterial and venous endothelial cell fate
was first understood with the discovery of Ephrin family
members. From recent reports on molecular mecha-
nisms for specification of arteriovenous identity, it is
evident that EFNB2 and EPHB4 markers are the end de-
terminants of arterial and vein specification, respectively.
Significance of EFNB2/EPHB4 signaling in arteriovenous
specification was first recognized by Wang HU, and their
study concluded that morphological differences between
arteries and veins are partly determined by genetic factors
[51]. It is now known that shear stress activates EFNB2
expression in murine embryonic stem cells through vascu-
lar endothelial growth factor (VEGF)-Notch signaling
[52]. Thus, it is evident that VEGF-Notch signaling path-
way determines the arterial specification and is controlled
by hemodynamic forces. The molecular distinction estab-
lished by EFNB2/EPHB4 are not a temporary characteris-
tics of the developing vascular system but have their
impact on adult arteries and veins as well [44]. The coor-
dinated action of Hedgehog-VEGF-Notch signaling cas-
cade is essential to control the arterial/venous fate during
development. Recent studies have revealed that VEGF acts
downstream of Sonic Hedgehog and upstream of the
Notch pathway and decides arterial endothelial cell fate
[53]. The role of Hedgehog-VEGF-Notch signaling in
controlling arterial endothelial cell fate is more evident
with identification of calcitonin receptor-like receptor
(CALCRL) as a novel element in Hedgehog-VEGF-Notch
signaling cascade. Somitic CALCRL expression is in turn
regulated by sonic hedgehog. Downregulation of CALCRL
affects VEGF expression, and CALCRL morphants are
characterized by the absence of expression of arterial
markers like EFNB2, Delta C, and Notch5 [54]. Notch sig-
naling pathway plays a pivotal role in differentiation of
endothelial cell to artery. Downregulation of Notch leads
to decreased expression of arterial specific markers EFNB2
and NOTCH3, along with constitutive increase of venous
markers like FLT4 and RTK5 [55]. Simultaneous activa-
tion of Notch along with β-catenin promotes arterial
endothelial cell formation from Flk1vascular progenitors
and maintains the arterial endothelial cell phenotype [56].
Notch signaling pathway in association with EFNB2/
EPHB4 determines the size of the blood vessel as well as
proportion of arterial and venous endothelial cells [57].
The Role of Notch in arterial specification is further clari-
fied by the discovery of gridlock signaling which acts
downstream of Notch. In zebrafish, downregulation of
gridlock expression transforms arterial phenotype to
venous [58]. It is evident that the cumulative actions of
molecular signaling and hemodynamic forces are crucial
for the proper development and maintenance of arteries
and veins; any dysregulation in these actions may lead to
the development of AVMs.
Do hemodynamic forces modulate the epigenetic
landscape in AVM?
Both genetic and epigenetic factors determine the iden-
tity of endothelial cell in an artery or a vein or a
Table 1 Known vascular markers specific for arteries and veins
S. no Arterial markers Venous markers
1 EFNB2 EPHB4
2 Delta-like 4 (DLL4) Neuropilin 2 (NRP2)
3 Activin-receptor-like kinase 1 (ACVRL1) COUP-TFII
4 Endothelial PAS domain protein 1 (EPAS1) FLT4
5 HEY1 RTK5
6 HEY2
7 Neuropilin 1 (NRP1)
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capillary. Hove et al. (2003) showed that intracardiac
fluid forces regulate the various epigenetic factors during
embryonic cardiogenesis. Their study established the fact
that in response to flow-induced forces, cultured cardiac
endothelial cells remodel their cytoskeletal structures
and change their gene expression profiles [59]. Connec-
tion between hemodynamic forces and epigenetic modu-
lators were studied in detail by Illi et al. They reported
the exposure of endothelial cells to shear stress results in a
series of chromatin modifications which causes changes in
gene expression in these cells [60]. The causes for develop-
ment of AVMs in the human brain are still elusive. It is
widely speculated that altered hemodynamic forces at the
junction of an artery and a vein might provoke the devel-
opment of AVM and hemodynamic forces may be the crit-
ical epigenetic regulator in deciding the endothelial fate
[61]. AVM is a high-flow vascular abnormality, and cere-
bral hemodynamic flow changes have an important role in
AVM pathophysiology, which includes hemorrhage, ische-
mia, and seizures [62, 63]. Two important hemodynamic
parameters like blood pressure and wall shearing stress
induce vascular remodeling. It has been described that
immense wall shearing stress and circumferential strain in
AVM feeders activate endothelial changes, which results in
increased expression of factors like matrix metalloprotease
9, platelet-derived growth factor, and VEGF that eventually
induce vascular remodeling in humans [64–68]. Studies in
activin receptor-like kinase 1 deficient mice model suggest
that change in the wall shearing stress induces higher
expression of VEGF, which leads to the formation of
distended vessels in the mouse brain. The vascular
morphological features in activin receptor-like kinase 1
deficient mice are very similar to those of AVMs in
humans [69, 70]. All existing studies suggest that the
abrupt changes in the hemodynamic flow in the junction
of arteriovenous blood vessels might strongly influence the
epigenetic mediators and eventually lead to the develop-
ment of AVM (Fig. 2). It has been reported that disturbed
shear pressure and altered hemodynamic forces cause
endothelial dysfunction at the arterial branches and
curvatures of blood vessels [71]. In addition, dis-
rupted shear and oscillatory hemodynamic pressure
activates many atherogenic genes in endothelial cells
and promotes atherosclerosis [72]. Various epigenetic
factors could be involved in the development of AVM
due to variations in hemodynamic forces.
DNA methylation and methyltransferases in AVM
The development of cells and their differentiation are
controlled by several epigenetic regulators. DNA methy-
lation is a key mechanism of epigenetic regulation in
higher eukaryotes. The DNA methylation reaction is cat-
alyzed by a group of enzymes called DNA methyltrans-
ferases which uses S-adenosyl-L-methionine as methyl
donor [73]. In humans, there are two groups of DNA
methyltransferases, DNMT3A and DNMT3B. These en-
zymes are de novo DNA methyltransferases and set the
initial DNA methylation patterns during development.
DNMT1 enzyme copies the DNA methylation pattern
from parental strand to daughter strand during DNA
replication [74, 75]. The methylation of CpG sites at
gene promoter causes the stable silencing of gene
Fig. 2 a Schematic representation of how aberrant hemodynamic forces cause altered arteriovenous shunting and further develops into AVM.
b The altered blood forces may result in aberrant epigenetic landscape with possibility of hypo- or hyper-DNA methylations and alterations of
various histone modifications and lead to AVM
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expression, and it is essential during early embryonic
development. These DNA methylation marks are im-
portant for the establishment of totipotency or pluripo-
tency as well as for health later in life [76]. In addition,
DNA methylation has a pivotal role in X-chromosome
inactivation, maintaining cell pluripotency, genomic
imprinting, and cellular integrity. Aberrant DNA methy-
lation pattern is a well-characterized epigenetic hallmark
in several pathologies particularly in many cancers. It is
known that aberrant expression of DNMTs and aberrant
DNA methylation signatures occur in various cancers,
cardiac development, and vascular developmental dis-
eases [77, 78]. The presence of hypomethylation at
global level with increased transcriptional activity in
endothelial cells of artery during atherogenesis process
suggests that local stimuli in endothelial cells of an
artery can bring changes at DNA methylation level in
their genome [79]. It has been shown that the differen-
tial methylation of promoter of endothelial nitric oxide
synthase (eNOS) gene contributes to vascular function,
indicating DNA methylation plays a significant role in
maintaining endothelial cell function [80]. It is known
that the artery and vein are functionally and morpho-
logically different; importantly, their endothelial cells
have marked variation in the level of DNA methylations
in their genome. Recently, Joo et al. reported the pres-
ence of differential methylation between artery and ven-
ous endothelial cell types [81]. They also observed
inverse relation between gene expression and promoter
methylation of a subset of genes and that such DNA
methylation pattern functionally reflected in endothelial
cell function [81]. The MeCP2 and ubiquitin-like PHD
and RING finger domain-containing proteins are
methyl-binding proteins, known to interact with the
DNMTs and regulate their activity. The methyl-binding
proteins bind to 5-methyl cytosine with high affinity and
further modulate the local gene activity [82]. It has been
shown that in vascular endothelial cells, methyl-binding
proteins bind to methylated promoters of eNOS and
vascular endothelial growth factor receptor 2 (VEGFR2)
[83]. Ablation of methyl-binding proteins in these cells
leads to activation of eNOS and VEGFR2 gene expres-
sion and stimulates proangiogenetic signal pathway.
Therefore, it is obvious that DNA methylation and bind-
ing of its effector proteins to methylated DNA is essen-
tial for vascular function and their development [83].
The presence of somatic mutations in various epigenetic
proteins has been observed in acute myeloid leukemia
and leads to the development of aberrant epigenetic
landscape [84, 85]. Thus, we speculate the presence of
aberrant epigenetic landscape in AVM, particularly ac-
quired mutations in epigenetic proteins and alterations
of DNA methylations in the promoters of vascular
developmental specific pathway genes (Fig. 2). A detailed
study on the DNA methylome of AVM tissues would
help us to delineate the aberrant vascular pathway genes
associated with AVMs.
Chromatin modifiers in AVMs
The N-terminus of histone tails in eukaryotes is sub-
jected to many post-translational modifications. Among
these, lysine acetylation and lysine methylation are the
major modifications which regulate chromatin structure
and local gene activity [86]. Epigenetic modifications in
the histone tails of endothelial cells in various physio-
logical conditions are the central theme of this review.
Therefore, we have focused only acetylation and methy-
lation of histone tails in endothelial cells. Endothelial
cells are component of blood vessel, which are exposed
to shear stress during aberrant blood flow condition.
Shear stress a component of hemodynamic forces in-
duces modifications at the core histones H3 and H4,
particularly acetylation and phosphorylation at H3 tails,
and this is a pre-requisite for shear stress-dependent ex-
pression of genes in endothelial cells [87]. Hemodynamic
force-induced histone acetylation, particularly changes of
its enzyme histone acetyl transferases (HATs) and his-
tone deacetyl transferases (HDACs), has been studied in
detail in the recent years [88]. It has been shown that
class I HDAC1/2/3 molecules modulate the endothelial
cell proliferation in response to oscillatory blood flow
[89]. Disturbed blood flow changes the post-translational
modifications of chromatin, which causes the changes in
chromatin structure [89]. Many other studies have re-
vealed that shear stress triggers the HDAC7 function
during angiogenic process, and it is essential during dif-
ferentiation of vascular endothelial cells and regenerative
process [87]. There are reports that global inhibition of
class I and II HDACs impairs angiogenesis process and
that downregulation of HDAC7 expression impairs the
development of the normal vasculature [90]. Using small
interfering RNA (siRNA) approach, Mottet et al. showed
that HDAC7 is crucial for the development of blood
vessels. They observed that silencing of HDAC7 in
endothelial cells altered the cell morphology, migra-
tion, and the capacity of cells to form capillary tube-
like structures [90]. Although many studies have
explored the role of histone acetylation in vascular
development, there are no reports regarding histone
methylation. A detailed enquiry is therefore war-
ranted for analysis of methylation at H3 tail at K4,
K9, K36, and H4 tail K20 positions in endothelial
cells under various hemodynamics conditions. Methy-
lation at these positions largely influences the gene
activity, and we hypothesize that hemodynamic blood
flow could affect these methylation marks and alter
the epigenetic landscape and chromatin structure in
developing blood vessels. These mechanisms could be
Thomas et al. Clinical Epigenetics  (2016) 8:78 Page 5 of 8
involved in the pathogenesis of AVM (Fig. 2). The
role of any other epigenetic modifications and en-
zymes in the regulation of early and late phases of
vascular development is currently unknown, and
further studies are required to understand such epi-
genetic mechanisms in AVM development.
Conclusions
Arteriovenous malformations are congenital develop-
mental disorders seen at many sites in the body.
Pathogenesis of AVM is still largely unknown, and no
specific markers have been identified for AVM. HHT
patients have symptoms similar to those in patients
with AVM. In HHT patients, polymorphism in TGF-
beta co-receptors endoglin and activin receptor-like
kinase 1 plays critical roles in the development of the
HHT lesions [29–32]. The possibility of combinatorial
changes at genetic and epigenetic levels in vascular
development may lead to the abnormal phenotype of
AVM. It is known that extensive tissue remodeling
occurs in AVM lesions and this may arise from the
changes in the epigenetic landscape of genes essential
for vascular development. All previous studies suggest
that development of AVMs requires stimuli to endo-
thelial cells in blood vessels, which could be either at
the transcriptional level or metabolite level in the
cytoplasm of endothelial cells. Altered transcription
could be due to changes at epigenetic makeup or at
the gene level. Changes in the metabolites in the
endothelial cells may also trigger AVM development.
A detailed study of the epigenetic signals of genes
associated with vascular development pathways could
throw light on the genetic and epigenetic mechanisms
in the development of AVMs.
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